CYP2C9-Guided S1P Modulator Dosing for Metabolic Variability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing S1P receptor modulators like BAF312 exhibit varying side effects and metabolic responses in patients due to differences in metabolism, necessitating personalized treatment regimens to optimize efficacy and safety.
Innovation Solution
Assessing patient genotypes for CYP2C9 metabolism to tailor BAF312 administration, including adjusting doses, timing, and combining with CYP2C9 promoters to manage side effects and improve therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a standard therapeutic dose of BAF312 is administered to all patients, then treatment simplicity is maintained, but patient safety and efficacy are compromised due to varying metabolic responses
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage parameter of BAF312 based on patient genotype. Patients with the CYP2C9*3/*3 genotype receive a reduced dose (0.25-0.75 mg/day) compared to the standard dose (1.0-2.0 mg/day) for other genotypes. This dosage parameter adjustment resolves the contradiction by maintaining treatment simplicity through clear genotype-based dosing guidelines while improving patient safety and efficacy for those with altered metabolism.
2Reliability
If genotype testing is performed for CYP2C9 to personalize dosing, then patient safety and efficacy are improved, but treatment complexity and cost increase
Solution Approach 1:
The patent applies preliminary action by performing CYP2C9 genotype testing before initiating BAF312 treatment. This preliminary genetic assessment allows clinicians to pre-determine the appropriate dosage regimen, avoiding the need for complex real-time monitoring and adjustment during treatment. The preliminary action simplifies the overall treatment process by establishing a fixed dosing strategy upfront, despite the initial testing requirement.
3Reliability
If dose titration is used to manage negative chronotropic effects, then patient safety is improved, but treatment duration and complexity increase
Solution Approach 1:
The patent applies local quality by implementing genotype-specific dosing strategies. Patients with the CYP2C9*3/*3 genotype receive a locally adjusted reduced dose from the outset, while other genotypes receive the standard dose with routine monitoring. This localized approach to dosing improves patient safety for those at risk without unnecessarily extending treatment duration for all patients, thereby resolving the contradiction between safety improvement and treatment duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Personalized dosing and timing strategies based on patient metabolism improve the risk-benefit ratio and minimize adverse effects, enhancing treatment efficacy for autoimmune conditions.
Implementation Method 1
CYP2C9 is the main enzyme responsible for the oxidative metabolism of BAF312 in the human liver
Implementation Method 2
These are compounds which signal as agonists at one or more sphingosine-1 phosphate receptors, for example, S1P1 to S1P8. The binding of an agonist to a S1P receptor may, for example, result in the dissociation of intracellular heterotrimeric G-proteins into Gα-GTP and Gβγ-GTP
Data Source
AI summary
The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof, comprising the steps of:(i) testing whether or not the patient has the poor metabolizer genotype; and(ii) if the patient does not have the poor metaboliser genotype, administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at the standard therapeutic dose; and(iii) if the patient does have the poor metaboliser genotype, either(a) administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient at a therapeutic dose below that of the standard therapeutic dose; or(b) not administering 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, to the patient.